Skip to main content

Development of a new DNA array-based diagnostic system (IBDchip) to predict clinical course, development of complications, and response to therapy in patients with inflammatory bowel disease (IBD)

Objective

Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). Both are increasingly common, chronic illnesses, currently affecting nearly 1 million patients in Europe. CD and UC affect patients early in life, seriously impairing their quality of life and resulting in enormous personal, social, and economic costs.There is evidence suggesting that genetic factors play a key role in IBD pathogenesis, pointing towards a polygenic mode of inheritance for CD and UC. However, to date studies have only addressed the influence of single mutations on IBD, resulting in a poor prediction of clinical course or response to therapy in individual patients. The IBDchip Project will develop an easy to use DNA array. This non-invasive tool will allow the simultaneous analysis of around 100 relevant mutations to predict the clinical evolution, the risk of developing IBD-related complications, and the likelihood of responding to certain drugs of each IBD patient. The project will have four main phases of work: 1. Two main retrospective studies including 1000 CD and 1000 UC patients across Europe. These studies will be aimed at defining the best combination of mutations resulting in an optimal prediction of each clinical outcome. 2. Three prospective studies specifically designed to address prediction of patients' response to immunosuppressive and anti-TNF therapies, which will validate the information provided by the retrospective studies. 3. A technical optimization process of the IBDchip, expected to result in a faster, cheaper, and easier to use tool. 4. Finally, the exploration of pathways to clinical service, ethical and legal issues, and cost-effectiveness of the IBDchip, to ensure its uptake in routine clinical practice. The main outcome of this project will be to provide doctors, for the first time, with a non-invasive, predictive tool to optimize treatment in IBD patients, thus resulting in better clinical outcomes and cost-effectiven'

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

CONCORCI INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER
Address
Villarroel 170
Barcelona
Spain

Participants (8)

PROGENIKA BIOPHARMA, S.A.
Spain
Address
Parque Tecnológico De Zamudio, Edificio 801
Derio
INNOPSYS
France
Address
Parc D'activités Activestre
Carbonne
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
University Offices, Wellington Square
Oxford
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven
UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN
Germany
Address
Brunswiker Str. 10
Kiel
GENERAL TEACHING HOSPITAL IN PRAGUE
Czechia
Address
U Nemocnice 2
Prague 2
HUMANITAS MIRASOLE SPA
Italy
Address
Via Manzoni, 56
Rozzano
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG
Netherlands
Address
De Boelelaan 1117
Amsterdam